Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Anyara naptumomab estafenatox: Additional Phase II/III data

In a subgroup analysis of the 25% of patients with low or normal levels of baseline IL-6 and expected anti-superantigen antibody levels, Anyara plus IFN alpha led to a median OS of 63.3 months vs. 31.1 months for IFN alpha

Read the full 405 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE